论文部分内容阅读
目的观察曲美他嗪治疗病毒性心肌炎并心力衰竭的疗效。方法选择48例病毒性心肌炎并心力衰竭患者,随机分为治疗组(24例)和对照组(24例),对照组为常规治疗,治疗组在常规治疗基础上加用曲美他嗪口服,观察两组治疗前后心功能变化、心电图ST-T改变、左室收缩未期容积(LVESD)、左室射血分数(LVEF)变化。结果治疗后治疗组心功能改善总有效率87.5%,明显大于对照组的70.8%(P<0.05);心电图ST-T改变治疗组总有效率95.8%,对照组75.0%(P<0.01);治疗组LVESD、LVEF和对照组比较差异有统计学意义(P<0.05)。结论曲美他嗪能有效地治疗病毒性心肌炎并心力衰竭的患者。
Objective To observe the efficacy of trimetazidine in the treatment of viral myocarditis and heart failure. Methods 48 patients with viral myocarditis and heart failure were randomly divided into treatment group (24 cases) and control group (24 cases). The control group was treated routinely. The treatment group was treated with trimetazidine, The changes of cardiac function, ECG ST-T changes, LVESD and LVEF before and after treatment were observed. Results After treatment, the total effective rate of the treatment group was 87.5%, significantly higher than that of the control group (70.8%, P <0.05). The total effective rate was 95.8% in the ST - T electrocardiogram treatment group and 75.0% (P <0.01) in the control group. The difference of LVESD, LVEF between the treatment group and the control group was statistically significant (P <0.05). Conclusion Trimetazidine is effective in the treatment of patients with viral myocarditis and heart failure.